ebomi
Colour theme
Sign in
Insider · CIK 0001249675

Perceptive Life Sciences Master Fund Ltd

CIK 0001249675 Name as filed on the most recent filing

Filed as Perceptive Life Sciences Master Fund Ltd (318)

817 transaction lines · from 318 filings · filed 2003-08-08 to 2025-11-13 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised. The 40 most recent are shown; the catalog may hold more for this insider.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-11-13 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 124,062, disposed Open Form 4 filing 0001193125-25-280481
2025-11-12 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 35,499, disposed Open Form 4 filing 0001193125-25-280481
2025-11-11 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 22,954, disposed Open Form 4 filing 0001193125-25-280481
2025-11-10 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 83,995, disposed Open Form 4 filing 0001193125-25-274540
2025-11-07 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 93,695, disposed Open Form 4 filing 0001193125-25-274540
2025-11-06 S, Open-market sale Lyra Therapeutics, Inc.LYRA 2 lines 166,529, disposed Open Form 4 filing 0001193125-25-274540
2025-08-01 P, Open-market purchase Orchestra BioMed Holdings, Inc.OBIO 1,925,000, acquired Open Form 4 filing 0000950170-25-102537
2025-05-01 S, Open-market sale Acrivon Therapeutics, Inc.ACRV 400,507, disposed Open Form 4 filing 0001062993-25-008341
2025-04-30 S, Open-market sale Acrivon Therapeutics, Inc.ACRV 617,412, disposed Open Form 4 filing 0001062993-25-008341
2025-04-29 S, Open-market sale Acrivon Therapeutics, Inc.ACRV 352,500, disposed Open Form 4 filing 0001062993-25-008214
2025-04-28 S, Open-market sale Acrivon Therapeutics, Inc.ACRV 335,841, disposed Open Form 4 filing 0001062993-25-008214
2025-04-25 S, Open-market sale Acrivon Therapeutics, Inc.ACRV 2,056,605, disposed Open Form 4 filing 0001062993-25-008214
2025-04-03 S, Open-market sale Aldeyra Therapeutics, Inc.ALDX 4,828,000, disposed Open Form 4 filing 0001062993-25-007163
2025-02-19 P, Open-market purchase Solid Biosciences Inc.SLDB 20,150,000, acquired Open Form 4 filing 0001062993-25-003153
2024-08-12 P, Open-market purchase MeiraGTx Holdings plcMGTX 5,000,000, acquired Open Form 4 filing 0001062993-24-015109
2024-04-11 P, Open-market purchase Acrivon Therapeutics, Inc.ACRV 20,000,500, acquired Open Form 4 filing 0001062993-24-008378
2024-04-05 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 178,755, acquired Open Form 4 filing 0001062993-24-008171
2024-04-04 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 655,112, acquired Open Form 4 filing 0001062993-24-008171
2024-04-03 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 1,267,274, acquired Open Form 4 filing 0001062993-24-007959
2024-04-02 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 640,015, acquired Open Form 4 filing 0001062993-24-007959
2024-04-01 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 27,216, acquired Open Form 4 filing 0001062993-24-007959
2024-02-01 P, Open-market purchase Astria Therapeutics, Inc.ATXS 29,999,522, acquired Open Form 4 filing 0001062993-24-001979
2024-01-11 P, Open-market purchase Solid Biosciences Inc.SLDB 18,861,243, acquired Open Form 4 filing 0001062993-24-000843
2023-12-29 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 838,204, acquired Open Form 4 filing 0001062993-23-023292
2023-12-29 P, Open-market purchase Athira Pharma, Inc.ATHA 390,211, acquired Open Form 4 filing 0001062993-23-023291
2023-12-28 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 892,901, acquired Open Form 4 filing 0001062993-23-023292
2023-12-28 P, Open-market purchase Athira Pharma, Inc.ATHA 999,419, acquired Open Form 4 filing 0001062993-23-023291
2023-12-27 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 574,027, acquired Open Form 4 filing 0001062993-23-023292
2023-12-27 P, Open-market purchase Athira Pharma, Inc.ATHA 73,266, acquired Open Form 4 filing 0001062993-23-023291
2023-12-26 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 354,691, acquired Open Form 4 filing 0000899243-23-020691
2023-12-22 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 1,667,500, acquired Open Form 4 filing 0000899243-23-020691
2023-12-21 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 1,234,000, acquired Open Form 4 filing 0000899243-23-020691
2023-12-21 P, Open-market purchase Astria Therapeutics, Inc.ATXS 4,588,000, acquired Open Form 4 filing 0001062993-23-023077
2023-12-19 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 1,484,763, acquired Open Form 4 filing 0001062993-23-022861
2023-12-18 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 2,471,953, acquired Open Form 4 filing 0001062993-23-022861
2023-12-15 P, Open-market purchase Verrica Pharmaceuticals Inc.VRCA 2,985,000, acquired Open Form 4 filing 0001062993-23-022861
2023-11-14 P, Open-market purchase Cargo Therapeutics, Inc.CRGX 2 lines 9,999,990, acquired Open Form 4 filing 0001062993-23-020811
2023-10-18 S, Open-market sale Aldeyra Therapeutics, Inc.ALDX 533,308, disposed Open Form 4 filing 0001062993-23-019546
2023-10-16 S, Open-market sale Aldeyra Therapeutics, Inc.ALDX 3,920,000, disposed Open Form 4 filing 0001062993-23-019546
2023-10-16 P, Open-market purchase Astria Therapeutics, Inc.ATXS 2 lines 6,999,997, acquired Open Form 4 filing 0001062993-23-019533
2023-10-16 P, Open-market purchase Cerevel Therapeutics Holdings, Inc.CERE 19,999,990, acquired Open Form 4 filing 0001062993-23-019470
2023-09-28 P, Open-market purchase Soleno Therapeutics IncSLNO 5,000,000, acquired Open Form 4 filing 0001062993-23-018574

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001249675

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.